Questions discussed in this category
Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?
http://www.nejm.org/doi/full/10.1056/NEJMoa1612645?rss=searchAndBrowse&#article_abstract
If so, how do you sequence it with adjuvant radiotherapy...
Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?
(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...
2012924186821921891
Papers discussed in this category
N. Engl. J. Med.,
ESMO Open, 2016-01-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Breast Cancer Res. Treat., 2014-09-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10
Lancet Oncol., 2014-06-01